Advisory Board

Dr. Beratan is an accomplished professor and researcher whose theories on complex molecular and macromolecular systems resulted in the technology behind the Quantum Molecular Design process. Dr. Beratan is affiliated with the Departments of Chemistry, Biochemistry, and Physics, as well as Duke's programs in Computational Biology and Bioinformatics, Structural Biology and Biophysics, Nanosciences, and Phononics. He is developing theoretical approaches to understand the function of complex molecular and macromolecular systems including a method to navigate the vastness of molecular space in order to discover promising new structures of use in biomedical, energy, and materials science. He has published more than 200 research papers and has produced one film. He has presented over 200 invited lectures internationally and serves on two editorial advisory boards.

Harold “Skip” Garner, PhDDirector, Medical Informatics and Systems Division Virginia Bioinformatics Institute, Virginia TechDr. Garner is a noted biophysicist with a distinguished research career focused on plasma physics, bioengineering, genetics, genomics, bioinformatics, and ethics. His expertise in genomics, drug targets, and biomarker discovery supports Cloud Pharmaceuticals’ drug design and development efforts. Dr. Garner is the founder of several biotechnology companies and has published widely in leading peer-reviewed journals throughout his career. He sits on several corporate advisory boards and advises government and private agencies, including the HHS, NIH, DoE, NASA, MacArthur Foundation, State Department and a variety of foreign countries.

Robert A. Hromas, MD, FACPChairman, University of Florida Department of MedicineDr. Hromas is an international authority in blood cancers and a leader in translational research and drug discovery in cancer therapies. He has published more than 150 research articles, has two patents, and three patents pending, for novel cancer therapies. He has access to many renowned investigators with novel targets, which helps to advance Cloud Pharmaceuticals’ research and development efforts. He currently holds more than $3.5 million in grants, and his research has been continuously funded since 1992 by the National Institutes of Health, with additional funding from the Leukemia and Lymphoma Society. He has been elected a Fellow of the American College of Physicians, a member of the American Society of Clinical Investigation, and a member of the Association of American Physicians.

Martin Ogletree, PhDOwner, Points & Assists – CV Research and Drug DevelopmentAdjunct Professor of Pharmacology, Vanderbilt University School of Medicine

Dr. Ogletree is a research and drug development expert who has applied more than 35 years of expertise at some of the industry’s most well-known and respected institutions including Vanderbilt University, Bristol-Myers Squibb, Cumberland Pharmaceuticals, and Merck. Dr. Ogletree is trained in cardiovascular and pulmonary physiology and pharmacology with specialized expertise in thrombosis, bleeding, platelet function, blood coagulation, inflammation and vascular biology and related biomarkers. He has a clear perspective on assessments of benefits versus risks for acute and chronic therapies, return on investment in R&D, and cost-effectiveness of pharmacotherapy. His guidance is of great value as Cloud Pharmaceuticals expands its drug development activity.

Dr. Vaught is a neurological disorder expert with more than 35 years of pharmaceutical R&D experience. Most recently, he served as the Chief Scientific Officer and Executive Vice President of Cephalon prior to its acquisition by TEVA Pharmaceuticals. In this capacity he had direct responsibilities for all non-clinical R&D managing over 400 scientists worldwide. Previously, Dr. Vaught was Assistant Director, CNS Research, for the R.W.J. Pharmaceutical Research Institute (a Johnson & Johnson subsidiary), and served as central nervous system therapeutic area team leader for Johnson & Johnson. An accomplished researcher, Dr. Vaught has published more than 125 peer reviewed scientific articles in the field of neurobiology. His drug discovery and development experience expertise is of great value to Cloud Pharmaceuticals as we pursue our mission to improve health and well-being through the computational design and rapid development of low-cost and effective therapies.